The Zynerba Pharmaceuticals (NASDAQ:ZYNE) Share Price Is Up 43% And Shareholders Are Holding On

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

Vanguard founder Jack Bogle helped spearhead the low-cost index fund, putting average returns within reach of every investor. But you can make better returns by buying undervalued shares. For example, the Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) share price is up 43% in the last three years, slightly above the market return. Zooming in, the stock is up just 2.3% in the last year.

View our latest analysis for Zynerba Pharmaceuticals

With just US$86,000 worth of revenue in twelve months, we don’t think the market considers Zynerba Pharmaceuticals to have proven its business plan. As a result, we think it’s unlikely shareholders are paying much attention to current revenue, but rather speculating on growth in the years to come. Investors will be hoping that Zynerba Pharmaceuticals can make progress and gain better traction for the business, before it runs low on cash.

As a general rule, if a company doesn’t have much revenue, and it loses money, then it is a high risk investment. There is usually a significant chance that they will need more money for business development, putting them at the mercy of capital markets. So the share price itself impacts the value of the shares (as it determines the cost of capital). While some such companies go on to make revenue, profits, and generate value, others get hyped up by hopeful naifs before eventually going bankrupt.

When it last reported its balance sheet in March 2019, Zynerba Pharmaceuticals had cash in excess of all liabilities of US$61m. That’s not too bad but management may have to think about raising capital or taking on debt, unless the company is close to breaking even. Given the share price has increased by a solid 13% per year, over 3 years, its fair to say investors remain excited about the future, despite the potential need for cash. The image below shows how Zynerba Pharmaceuticals’s balance sheet has changed over time; if you want to see the precise values, simply click on the image.

NasdaqGM:ZYNE Historical Debt, June 11th 2019
NasdaqGM:ZYNE Historical Debt, June 11th 2019

It can be extremely risky to invest in a company that doesn’t even have revenue. There’s no way to know its value easily. Given that situation, many of the best investors like to check if insiders have been buying shares. If they are buying a significant amount of shares, that’s certainly a good thing. You can click here to see if there are insiders buying.

A Different Perspective

Zynerba Pharmaceuticals produced a TSR of 2.3% over the last year. Unfortunately this falls short of the market return of around 2.7%. But the (superior) three-year TSR of 13% per year is some consolation. Even the best companies don’t see strong share price performance every year. It is all well and good that insiders have been buying shares, but we suggest you check here to see what price insiders were buying at.

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.